Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients

Update Il y a 4 ans
Reference: NCT00280917

Woman and Man

Extract

This trial will test the hypothesis that the addition of CF101, a novel anti-inflammatory agent, will improve the clinical condition of patients with rheumatoid arthritis who still have active joint inflammation despite taking methotrexate for at least 6 months.


Inclusion criteria

  • Rheumatoid Arthritis


Links